Internal Medicine · Jackson Heights, NY
NPI
1144394784
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
3751 91st St
Jackson Heights, NY, 11372
Phone (718) 205-5355
Medicare paid, 2024
$17K
388 services
Medicare patients, 2024
76
Average age 74
Drug cost, 2024
$1.3M
13,441 prescriptions
Company payments, 2025
$1,951
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jaime F Roman was code 36415 (venipuncture blood collection), 114 times for 68 patients. In total Jaime F Roman billed 388 services in 20 codes, and Medicare paid $17K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-09-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 114 | 68 | $8.65 | $986 |
| 99213 Office E&M - Established | Office | 78 | 51 | $72.29 | $5,639 |
| G0442 Annual alcohol misuse screening, 5 to 15 minutes | Office | 46 | 46 | $21.46 | $987 |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 45 | 45 | $21.45 | $965 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 40 | 40 | $144.76 | $5,790 |
By year: 2022 $28K for 448 services; 2023 $19K for 367 services; 2024 $17K for 388 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 114 | 68 | $8.65 | $986 |
Medicare prescription drug claims, 2024
In 2024, the drug Jaime F Roman prescribed most often to Medicare patients was Atorvastatin Calcium, with 1,091 prescriptions and refills. In total Jaime F Roman wrote 13,441 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 1,091 | 3,160 | 399 | $14K |
| Amlodipine Besylate Generic | 839 | 2,454 | 305 | $6,268 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 703 | 1,915 | 322 | $2,913 |
| Losartan Potassium Generic | 655 | 1,891 | 232 | $7,662 |
| Metformin Hcl Generic | 533 | 1,532 | 187 | $3,950 |
| Simvastatin Generic | 527 | 1,560 | 187 | $4,442 |
| Levothyroxine Sodium Generic | 522 | 1,538 | 180 | $8,419 |
| Omeprazole Generic | 452 | 1,263 | 174 | $7,293 |
| Pioglitazone Hcl Generic | 386 | 1,128 | 131 | $4,733 |
| Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide | 342 | 991 | 132 | $16K |
| Zolpidem Tartrate Generic | 289 | 289 | 72 | $1,741 |
| Rosuvastatin Calcium Generic | 270 | 797 | 104 | $4,758 |
| Montelukast Sodium Generic | 229 | 649 | 101 | $2,752 |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | 223 | 656 | 89 | $5,797 |
| Valsartan Generic | 187 | 552 | 70 | $6,001 |
Brand drugs: 1,354 claims; generic drugs: 11,999 claims; opioid claims: 42.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jaime F Roman $1,951 ($1,951 in general payments such as food, travel and fees) from 13 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $564.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 15 | $564 |
| Novo Nordisk Inc NVO | 12 | $375 |
| Amgen Inc. AMGN | 9 | $314 |
| Ardelyx, Inc. ARDX | 10 | $250 |
| Travere Therapeutics, Inc. TVTX | 4 | $95.86 |
| Gilead Sciences, Inc. GILD | 3 | $67.61 |
| Exact Sciences Corporation EXAS | 3 | $66.96 |
| Sumitomo Pharma America, Inc. 4506.T | 2 | $54.88 |
| Merck Sharp & Dohme LLC MRK | 2 | $51.51 |
| Biogen, Inc. BIIB | 2 | $39.73 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.